INDIANAPOLIS, May 23, 2018 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) announced today that Sue Mahony, Ph.D., senior vice president of
Lilly and president of Lilly Oncology, will retire at the end of
August after 18 years of service with the company. Mahony is also a
member of Lilly's executive committee.
"On behalf of our executive team and the company, I want to
thank Sue for her leadership over the past 18 years," said
David A. Ricks, Lilly's chairman and
chief executive officer. "Her passion for patients and strong sense
of purpose are inspiring to all of us."
Mahony led Lilly Oncology through the integration of ImClone,
successfully launched several key brands—including Verzenio™—and
most recently led the refocusing of the company's oncology R&D
strategy. Prior to this, as senior vice president of human
resources and diversity, Mahony played a key role in restructuring
the company into business units.
Mahony joined Lilly in 2000 after more than a decade in sales
and marketing roles in Europe for
Schering-Plough, Amgen and Bristol-Myers Squibb. At Lilly, Mahony
has held senior leadership positions in product development, Six
Sigma, marketing and general management roles.
"What I've appreciated over the years is the opportunity to
participate in something greater than myself," said Mahony. "We
make medicines that help patients with cancer live longer. What a
privilege it's been to wake up each morning with that as my life's
work."
Lilly is considering internal and external candidates to succeed
Mahony.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
C-LLY
This press release contains forward-looking statements
about leadership changes within Lilly's human pharmaceutical
business and reflects Lilly's current beliefs. There are risks and
uncertainties related to leadership changes, including with regard
to identifying a successor to Ms. Mahony and the timing of these
changes. For discussion of important risks and uncertainties,
please see Lilly's latest Forms 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission. Lilly undertakes no duty to
update forward-looking statements.
Refer to: Kelley Murphy;
kmurphy@lilly.com;
317-701-4007
View original content with
multimedia:http://www.prnewswire.com/news-releases/sue-mahony-to-retire-as-president-of-lilly-oncology-300653769.html
SOURCE Eli Lilly and Company